Comprehensive Psychiatry
Volume 51, Issue 3 , Pages 298-302 , May 2010

Nonresponse to clozapine and premorbid functioning in treatment refractory schizophrenia

References 

  1. Schmael C, Georgi A, Krumm B, Buerger C, Deschner M, Nothen MM, et al. Premorbid adjustment in schizophrenia—an important aspect of phenotype definition. Schizophr Res. 2007;92:50–62
  2. Picchioni MM, Toulopoulou T, Landau S, Davies N, Ribchester T, Murray RM. Neurological abnormalities in schizophrenic twins. Biol Psychiatry. 2006;59(4):341–348
  3. Walshe M, McDonald C, Grech A, Schulze K, Bramon E, Murray RM. Premorbid functioning in the unaffected siblings of patients with familial and nonfamilial schizophrenia. Schizophr Res. 2006;81(suppl 1):272
  4. Gornick MC, Addington AM, Sporn A, Gogtay N, Greenstein D, Lenane M, et al. Dysbindin (DTNBP1, 6p22.3) is associated with childhood onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). J Austism Dev Disord. 2005;35:831–838
  5. Addington J, Addington D. Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia. J Psychiatry Neurosci. 1993;18(1):18–23
  6. Strous RD, Alvir JM, Robinson D, gal G, Sheitman B, Chakos M, et al. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr Bull. 2004;30(2):265–278
  7. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495–506
  8. Amminger GP, Resch F, Mutschlechner R, Friedrich MH, Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur Child Adolesc Psychiatry. 1997;6:212–218
  9. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment in recent-onset schizophrenia. Br J Psychiatry. 2006;189:31–35
  10. Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Pardo-Garcia G, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res. 2007;41:659–666
  11. Tabatabaee M, Sharifi V, Alaghband-rad J, Amini H, Boroumand M, Omid A, et al. Acute treatment response and its predictors in patients with first-episode psychosis in Iran. Australas Psychiatry. 2008;16:125–129
  12. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome in first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(suppl 9):5–9
  13. Conley RC, Kelly DL. Management of treatment-resistant schizophrenia. Biol Psychiatry. 2001;50:898–911
  14. Friedman L, Knutson L, Shurell M, Meltzer HY. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry. 1991;29(9):865–877
  15. Caspi A, Reichenberg A, Weiser M, Rabinowitz J, Shmushkevich M, Lubin G, et al. Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs. Schizophr Res. 2007;94:45–49
  16. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470–484
  17. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119–123
  18. Hawk AB, Carpenter WT, Strauss JS. Diagnostic criteria and five-year outcome in schizophrenia. A report from the International Pilot Study of schizophrenia. Arch Gen Psychiatry. 1975;32:343–347
  19. Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry. 2002;159(7):1183–1189
  20. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, Schmeidler J, et al. Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005;62(12):1297–1304
  21. Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs. 2006;20:841–866
  22. Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, et al. for the Dept. of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia Predictors of differential response to clozapine and haloperidol. Biol Psychiatry. 1998;44:475–482
  23. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl). 1989;99(Suppl):S68–S72
  24. Stern RG, Kahn RS, Davidson M, Nora RM, Davis KL. Early response to clozapine in schizophrenia. Am J Psychiatry. 1994;151:1817–1818
  25. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002;63(5):420–424
  26. Brill N, Reichenberg A, Rabinowitz J, Harary E, Lubin G, Davidson M, et al. Accuracy of self-reported premorbid functioning in schizophrenia. Schizophr Res. 2007;97(1-3):103–108
  27. van Winkel R, Myin-Germeys I, Delespaul P, Peuskens J, De Hert M, van Os J. Premorbid IQ as a predictor for the course of IQ in first onset patients with schizophrenia: a 10-year follow-up study. Schizophr Res. 2006;88(1-3):47–54

PII: S0010-440X(09)00083-2

doi: 10.1016/j.comppsych.2009.07.003

Comprehensive Psychiatry
Volume 51, Issue 3 , Pages 298-302 , May 2010

Article Tools